Nintedanib Pliva (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, FGFR and PDGFR—thereby inhibiting pathways that drive fibroblast proliferation, new blood‑vessel formation and fibrotic tissue remodeling. This dual antifibrotic and anti‑angiogenic activity underlies its therapeutic effect in lung fibrosis and certain cancers.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s condition, renal and hepatic function, and concomitant therapies. Healthcare professionals should follow the approved prescribing information and adjust as needed.

Safety data for Nintedanib in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy unless the potential benefit justifies the risk, and breastfeeding should be discontinued while on therapy because drug excretion in milk cannot be excluded.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

For idiopathic pulmonary fibrosis, the primary alternative is pirfenidone, another antifibrotic agent with a different safety profile. Nintedanib’s multitarget kinase inhibition offers broader anti‑angiogenic activity, which can be advantageous in certain cancer regimens, whereas pirfenidone works mainly through anti‑inflammatory mechanisms.

Store Nintedanib Pliva at ambient temperature, preferably below 25 °C. Keep the product in its original packaging to protect it from moisture and light. Do not refrigerate or freeze the tablets, and retain them out of reach of children.

Nintedanib Pliva is taken orally, usually with food to lessen gastrointestinal discomfort. The tablets should be swallowed whole with a full glass of water and not crushed, chewed, or split unless specifically instructed by a healthcare professional.

Clinicians and patients should be vigilant for signs of severe liver injury (jaundice, dark urine), major bleeding events (hematuria, gastrointestinal hemorrhage), arterial thromboembolic episodes (chest pain, sudden weakness), and gastrointestinal perforation. Prompt medical evaluation is required if any of these occur.

Nintedanib is contraindicated in patients with severe hepatic impairment, active uncontrolled bleeding, recent major cardiovascular events, or known hypersensitivity to the drug. Caution is also advised for individuals with moderate liver disease, uncontrolled hypertension, or a history of gastrointestinal ulcers.